What is he best known for?
The fields of study he is best known for:
- Immune system
- Cytokine
- Internal medicine
Mark A. Exley spends much of his time researching Immunology, CD1D, Natural killer T cell, T cell and Antigen.
His research in Immunology intersects with topics in Animal model and Pharmacology.
His CD1D research is under the purview of Immune system.
His Natural killer T cell study incorporates themes from Molecular biology, Adoptive cell transfer and Antigen-presenting cell.
His T cell research is multidisciplinary, incorporating elements of Cytotoxic T cell and Cell biology.
Mark A. Exley focuses mostly in the field of Antigen, narrowing it down to topics relating to Macrophage and, in certain cases, Interleukin 4, Granulocyte macrophage colony-stimulating factor and Bronchoalveolar lavage.
His most cited work include:
- Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis (639 citations)
- Multiple immuno-regulatory defects in type-1 diabetes (618 citations)
- Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes (601 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Immunology, Natural killer T cell, CD1D, Immune system and T cell.
His is doing research in Cytokine, Immunotherapy, IL-2 receptor, Innate immune system and Antigen presentation, both of which are found in Immunology.
Mark A. Exley has researched Natural killer T cell in several fields, including Adoptive cell transfer, Antigen-presenting cell and Cell biology.
His studies deal with areas such as Cell and MHC class I as well as Cell biology.
His CD1D research includes elements of Inflammation and Cancer research.
His study in Molecular biology extends to T cell with its themes.
He most often published in these fields:
- Immunology (86.02%)
- Natural killer T cell (58.60%)
- CD1D (50.00%)
What were the highlights of his more recent work (between 2013-2021)?
- Immunology (86.02%)
- Natural killer T cell (58.60%)
- Immune system (43.01%)
In recent papers he was focusing on the following fields of study:
Mark A. Exley mainly focuses on Immunology, Natural killer T cell, Immune system, CD1D and T-cell receptor.
His research investigates the connection between Immunology and topics such as Peripheral blood mononuclear cell that intersect with problems in Asthma.
His biological study spans a wide range of topics, including Cell, Nod and Interleukin 12, Interleukin 21, Lymphokine-activated killer cell.
Mark A. Exley interconnects CD1 and Cell biology in the investigation of issues within CD1D.
His study looks at the relationship between T-cell receptor and fields such as Cancer research, as well as how they intersect with chemical problems.
His biological study spans a wide range of topics, including Receptor and Primary sclerosing cholangitis.
Between 2013 and 2021, his most popular works were:
- Interplay between the immune system and adipose tissue in obesity. (131 citations)
- Adipose Type One Innate Lymphoid Cells Regulate Macrophage Homeostasis through Targeted Cytotoxicity. (91 citations)
- Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial (66 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Cytokine
- Internal medicine
The scientist’s investigation covers issues in Immunology, Immune system, Natural killer T cell, CD1D and Immunotherapy.
His Immunology study integrates concerns from other disciplines, such as Receptor and Diet therapy.
His research in Immune system intersects with topics in Endocrinology and Internal medicine.
His Internal medicine research incorporates themes from Leukocyte homeostasis and Cytotoxic T cell.
Natural killer T cell is a subfield of Antigen that Mark A. Exley explores.
His CD1D study incorporates themes from Cell growth, MHC class I, Cell biology, Double negative and Flow cytometry.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
